227 related articles for article (PubMed ID: 17483544)
21. New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target.
Kourounakis AP; Bavavea E
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000085. PubMed ID: 32557793
[TBL] [Abstract][Full Text] [Related]
22. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.
Chan C; Andreotti D; Cox B; Dymock BW; Hutson JL; Keeling SE; McCarthy AD; Procopiou PA; Ross BC; Sareen M; Scicinski JJ; Sharratt PJ; Snowden MA; Watson NS
J Med Chem; 1996 Jan; 39(1):207-16. PubMed ID: 8568810
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].
Corsini A; Arnaboldi L; Quarato P; Ferri N; Granata A; Fumagalli R; Paoletti R
C R Seances Soc Biol Fil; 1997; 191(2):169-94. PubMed ID: 9255346
[TBL] [Abstract][Full Text] [Related]
24. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase.
Bergstrom JD; Dufresne C; Bills GF; Nallin-Omstead M; Byrne K
Annu Rev Microbiol; 1995; 49():607-39. PubMed ID: 8561474
[TBL] [Abstract][Full Text] [Related]
25. Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase.
Liu CI; Jeng WY; Chang WJ; Ko TP; Wang AH
J Biol Chem; 2012 May; 287(22):18750-7. PubMed ID: 22474324
[TBL] [Abstract][Full Text] [Related]
26. Cloning and characterization of the Arabidopsis thaliana SQS1 gene encoding squalene synthase--involvement of the C-terminal region of the enzyme in the channeling of squalene through the sterol pathway.
Kribii R; Arró M; Del Arco A; González V; Balcells L; Delourme D; Ferrer A; Karst F; Boronat A
Eur J Biochem; 1997 Oct; 249(1):61-9. PubMed ID: 9363754
[TBL] [Abstract][Full Text] [Related]
27. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo.
Baxter A; Fitzgerald BJ; Hutson JL; McCarthy AD; Motteram JM; Ross BC; Sapra M; Snowden MA; Watson NS; Williams RJ
J Biol Chem; 1992 Jun; 267(17):11705-8. PubMed ID: 1601846
[TBL] [Abstract][Full Text] [Related]
28. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
Wasko BM; Smits JP; Shull LW; Wiemer DF; Hohl RJ
J Lipid Res; 2011 Nov; 52(11):1957-64. PubMed ID: 21903868
[TBL] [Abstract][Full Text] [Related]
29. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
Bergstrom JD; Kurtz MM; Rew DJ; Amend AM; Karkas JD; Bostedor RG; Bansal VS; Dufresne C; VanMiddlesworth FL; Hensens OD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):80-4. PubMed ID: 8419946
[TBL] [Abstract][Full Text] [Related]
30. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
[TBL] [Abstract][Full Text] [Related]
31. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.
Vaidya S; Bostedor R; Kurtz MM; Bergstrom JD; Bansal VS
Arch Biochem Biophys; 1998 Jul; 355(1):84-92. PubMed ID: 9647670
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines.
McTaggart F; Brown GR; Davidson RG; Freeman S; Holdgate GA; Mallion KB; Mirrlees DJ; Smith GJ; Ward WH
Biochem Pharmacol; 1996 Jun; 51(11):1477-87. PubMed ID: 8630089
[TBL] [Abstract][Full Text] [Related]
33. Alterations in cell cholesterol content modulate Ca(2+)-induced tight junction assembly by MDCK cells.
Stankewich MC; Francis SA; Vu QU; Schneeberger EE; Lynch RD
Lipids; 1996 Aug; 31(8):817-28. PubMed ID: 8869884
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Ness GC; Zhao Z; Lopez D
Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
[TBL] [Abstract][Full Text] [Related]
35. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.
Oldfield E
Acc Chem Res; 2010 Sep; 43(9):1216-26. PubMed ID: 20560544
[TBL] [Abstract][Full Text] [Related]
36. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
Li HY; Appelbaum FR; Willman CL; Zager RA; Banker DE
Blood; 2003 May; 101(9):3628-34. PubMed ID: 12506040
[TBL] [Abstract][Full Text] [Related]
37. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.
Weivoda MM; Hohl RJ
Endocrinology; 2011 Aug; 152(8):3113-22. PubMed ID: 21586555
[TBL] [Abstract][Full Text] [Related]
38. Differential inhibition of host cell cholesterol de novo biosynthesis and processing abrogates Eimeria bovis intracellular development.
Hamid PH; Hirzmann J; Hermosilla C; Taubert A
Parasitol Res; 2014 Nov; 113(11):4165-76. PubMed ID: 25199551
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of Glycine max squalene synthase genes in seed phytosterol biosynthesis.
Nguyen HT; Neelakadan AK; Quach TN; Valliyodan B; Kumar R; Zhang Z; Nguyen HT
Plant Physiol Biochem; 2013 Dec; 73():23-32. PubMed ID: 24036394
[TBL] [Abstract][Full Text] [Related]
40. Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.
Ha NT; Lee CH
Cells; 2020 Oct; 9(11):. PubMed ID: 33113804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
